BNP Paribas Financial Markets Grows Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

BNP Paribas Financial Markets raised its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 346.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 10,433 shares of the company's stock after buying an additional 8,098 shares during the period. BNP Paribas Financial Markets' holdings in Krystal Biotech were worth $1,899,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Key Financial Inc purchased a new stake in Krystal Biotech during the second quarter valued at $28,000. GAMMA Investing LLC grew its stake in shares of Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company's stock valued at $28,000 after purchasing an additional 93 shares during the period. Blue Trust Inc. increased its position in shares of Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company's stock valued at $30,000 after purchasing an additional 163 shares during the last quarter. Values First Advisors Inc. purchased a new stake in shares of Krystal Biotech during the 3rd quarter valued at about $53,000. Finally, Quest Partners LLC bought a new position in shares of Krystal Biotech in the 2nd quarter worth approximately $71,000. 86.29% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on KRYS shares. Evercore ISI upped their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a report on Monday, August 12th. Stifel Nicolaus upped their price objective on Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a research note on Wednesday, September 11th. HC Wainwright reaffirmed a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a report on Tuesday, November 5th. Citigroup lifted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Finally, William Blair upgraded shares of Krystal Biotech to a "strong-buy" rating in a research note on Friday, August 30th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $202.29.

Krystal Biotech Price Performance

Shares of KRYS stock traded up $5.49 during mid-day trading on Friday, hitting $185.25. The company had a trading volume of 216,765 shares, compared to its average volume of 229,305. The company has a market capitalization of $5.33 billion, a P/E ratio of 104.66 and a beta of 0.80. The stock's 50 day moving average price is $181.27 and its 200-day moving average price is $184.52. Krystal Biotech, Inc. has a 52-week low of $101.34 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the prior year, the firm earned ($0.67) EPS. The business's revenue was up 879.9% on a year-over-year basis. On average, equities research analysts expect that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares of the company's stock, valued at approximately $296,814,424.32. This trade represents a 1.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.10% of the stock is currently owned by company insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).